GW Pharmaceuticals to Report Q3 Financial Results and Host Conference Call on 7 August, 2017
July 24 2017 - 2:00PM
GW Pharmaceuticals plc (Nasdaq:GWPH), (“GW” or “the Company”), a
biopharmaceutical company focused on discovering, developing and
commercializing novel therapeutics from its proprietary cannabinoid
product platform, will announce on 7 August, 2017 its third quarter
financial results for the period ending 30 June, 2017. GW will also
host a conference call the same day at 4:30 p.m. EDT. Conference
call information will be provided in the financial results press
release. A replay of the call will also be available through the
Company's website (www.gwpharm.com) shortly after the call.
About GW Pharmaceuticals
plc
Founded in 1998, GW is a biopharmaceutical
company focused on discovering, developing and commercializing
novel therapeutics from its proprietary cannabinoid product
platform in a broad range of disease areas. GW is advancing an
orphan drug program in the field of childhood epilepsy with a focus
on Epidiolex® (cannabidiol), which is in Phase 3 clinical
development for the treatment of Dravet syndrome, Lennox-Gastaut
syndrome, Tuberous Sclerosis Complex and Infantile Spasms. GW
commercialized the world’s first plant-derived cannabinoid
prescription drug, Sativex® (nabiximols), which is approved for the
treatment of spasticity due to multiple sclerosis in 30 countries
outside the United States. The Company has a deep pipeline of
additional cannabinoid product candidates which includes compounds
in Phase 1 and 2 trials for glioma, schizophrenia and epilepsy. For
further information, please visit www.gwpharm.com.
Enquiries:
GW Pharmaceuticals plc
Stephen Schultz, VP Investor Relations (U.S.) 917 280 2424 / 401 500 6570
GW Pharmaceuticals (NASDAQ:GWPH)
Historical Stock Chart
From Apr 2024 to May 2024
GW Pharmaceuticals (NASDAQ:GWPH)
Historical Stock Chart
From May 2023 to May 2024
Real-Time news about GW Pharmaceuticals PLC (NASDAQ): 0 recent articles
More News Articles